Skip to main content
Linda Laux, MD, Pediatrics, Chicago, IL, Northwestern Memorial Hospital

LindaCarolLauxMD

Pediatrics Chicago, IL

Child Neurology

Assistant Professor in Pediatrics, Northwestern University Medical School

Dr. Laux is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Laux's full profile

Already have an account?

Education & Training

  • Phoenix Children's Hospital
    Phoenix Children's HospitalFellowship, Child Neurology, 1994 - 1997
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Pediatrics, 1990 - 1993
  • Saint Louis University School of Medicine
    Saint Louis University School of MedicineClass of 1990

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2000 - 2023
  • AZ State Medical License
    AZ State Medical License 1994 - 2010
  • American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
  • American Board of Psychiatry and Neurology Clinical Neurophysiology
  • American Board of Psychiatry and Neurology Epilepsy

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Antisense Oligonucleotide Shows Potential in Dravet Syndrome
    Antisense Oligonucleotide Shows Potential in Dravet SyndromeDecember 9th, 2022
  • Stoke Therapeutics : Presents Data from a Combined Interim Analysis of the Phase 1/2a - Form 8-K
    Stoke Therapeutics : Presents Data from a Combined Interim Analysis of the Phase 1/2a - Form 8-KDecember 2nd, 2022
  • Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting
    Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual MeetingDecember 4th, 2020
  • Join now to see all

Hospital Affiliations